While GLP-1 receptor agonists were initiated for other health reasons, they were tied to less need for migraine prevention medications
MONDAY, March 2, 2026 (HealthDay News) — For people with chronic migraine (CM), taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with fewer emergency department visits and hospitalizations overall and less need for medications used to stop and prevent migraine attacks, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 18 to 22 in Chicago.
Vitoria Acar, from the University of Sao Paulo in Brazil, and colleagues compared health care utilization, triptan use, and preventive-treatment escalation following initiation of a GLP-1 RA versus topiramate in adults with CM. The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.
The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87). GLP-1 RA initiators also had a lower risk for initiation of tricyclic antidepressants (RR, 0.65), valproate (RR, 0.52), gepants (RR, 0.77), calcitonin gene-related peptide monoclonal antibodies (RR, 0.58), and serotonin-norepinephrine reuptake inhibitors (RR, 0.80). For beta-blocker initiation, there were no significant differences observed.
“Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven’t fully appreciated yet,” Acar said in a statement.
Therapies Compared for Newly Diagnosed Multiple Sclerosis 
Initial Rx Length Tied to Long-Term Use of Z-Drugs 
People Using Illicitly Sourced Fentanyl Face Worse Outcomes Than Medically Sourced Users 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer 
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women 
All-Cause Mortality Elevated for Adult Five-Year Survivors of Hodgkin Lymphoma 
Acute Myeloid Leukemia Increasingly Impacting Older Adults Globally 
